CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue:
Core companion animal health	$ 84,249	$ 72,354	$ 66,404
Other vaccines, pharmaceuticals and products	20,348	17,483	11,935
Total revenue, net	104,597	89,837	78,339
Cost of revenue	60,384	54,122	47,707
Gross profit	44,213	35,715	30,632
Operating expenses:
Selling and marketing	21,339	19,159	19,428
Research and development	1,658	1,414	1,500
General and administrative	12,659	12,231	11,134
Total operating expenses	35,656	32,804	32,062
Operating income (loss)	8,557	2,911	(1,430)
Interest and other expense (income), net	130	(39)	(37)
Income (loss) before income taxes	8,427	2,950	(1,393)
Income tax expense (benefit):
Current income tax expense	1,581	47	183
Deferred income tax expense (benefit)	1,327	1,304	(637)
Total income tax expense (benefit)	2,908	1,351	(454)
Net income (loss)	5,519	1,599	(939)
Net income (loss) attributable to non-controlling interest	280	(1,004)	257
Net income (loss) attributable to Heska Corporation	$ 5,239	$ 2,603	$ (1,196)
Earnings Per Share [Abstract]
Basic earnings (loss) per share attributable to Heska Corporation, in dollars per share	$ 0.80	$ 0.44	$ (0.21)
Diluted earnings (loss) per share attributable to Heska Corporation, in dollars per share	$ 0.74	$ 0.41	$ (0.21)
Weighted average outstanding shares used to compute basic earnings (loss) per share attributable to Heska Corporation	6,509	5,951	5,755
Weighted average outstanding shares used to compute diluted earnings (loss) per share attributable to Heska Corporation	7,074	6,409	5,755